YD Bio Limited (YDES)
| Market Cap | 363.91M +762.5% |
| Revenue (ttm) | 510,360 +45.8% |
| Net Income | -1.41M |
| EPS | -1.29 |
| Shares Out | 70.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,129 |
| Open | 5.36 |
| Previous Close | 5.06 |
| Day's Range | 5.18 - 5.36 |
| 52-Week Range | 4.73 - 25.00 |
| Beta | -0.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 30, 2026 |
About YDES
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
Financial Performance
Financial StatementsNews
YD Bio Limited Reports Full Year 2025 Financial Results
TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and op...
YD Bio Ltd trading halted, volatility trading pause
15:56 EDT YD Bio (YDES)Ltd trading halted, volatility trading pause
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and op...
YD Bio Ltd trading halted, volatility trading pause
09:43 EDT YD Bio (YDES)Ltd trading halted, volatility trading pause
YD Bio details roadmap for integrated oncology ecosystem
YD Bio (YDES)highlighted the strategic roadmap shared by CEO Ethan Shen. YD Bio is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution. By ...
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology an...
YD Bio announces partnership with YC Biotech
YD Bio (YDES)announced that its subsidiary YD Bio USA entered into a Master Strategic Alliance Agreement with YC Biotech on February 24, 2026. This partnership represents a pivotal advancement in…
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform
Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and...
YD Bio enters into binding LOI to acquire shares, assets of SSMC
YD Bio (YDES)announced it has entered into a binding Letter of Intent, LOI, to acquire all shares, assets, and business of Safe Save Medical Cell Sciences & Technology, SSMC. The…
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthal...
YD Bio enters MOU to merge with EG BioMed
YD Bio (YDES)announced that the Company has entered into a Memorandum of Understanding, MOU, to merge with EG BioMed. The MOU is non-binding and there can be no assurance that…
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and oph...
YD Bio unveils 2026 clinical, commercial roadmap
YD Bio (YDES)announced the completion of critical milestones across its core platforms: stem cell therapy & exosome platforms focused on ophthalmology conditions, early cancer detection powered by DNA...
YD Bio unveils 2026 clinical, commercial roadmap
YD Bio (YDES)announced the completion of critical milestones across its core platforms: stem cell therapy & exosome platforms focused on ophthalmology conditions, early cancer detection powered by DNA...
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and oph...
YD Bio announces newly planned California facilities, operations center
YD Bio (YDES)announced initiation of its latest plans for new facilities and a U.S. operations center in California to accelerate clinical development, regulatory engagement and commercial access for ...
YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center
Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and oph...
YD Bio showcases diagnostic, precision medicine portfolios
YD Bio (YDES)announced participation in the 9th Healthcare Expo Taiwan, which was held from December 4-7, 2025, at TaipeiNEX. The Company exhibited at Booth No. 4F, M1004, where it presented…
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN
Taipei, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and oph...
YD Bio provides update on OkaiDx testing portfolio
YD Bio (YDES)provided an update to its November 5, 2025 announcement regarding U.S. access to the OkaiDx platform for post-treatment breast cancer monitoring, detailing the continued expansion of Okai...
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection
Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and oph...
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics
Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and oph...
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring
Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and o...